Literature DB >> 26699808

International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer.

Kyoichi Takaori1, Claudio Bassi2, Andrew Biankin3, Thomas B Brunner4, Ivana Cataldo5, Fiona Campbell6, David Cunningham7, Massimo Falconi8, Adam E Frampton9, Junji Furuse10, Marc Giovannini11, Richard Jackson12, Akira Nakamura13, William Nealon14, John P Neoptolemos12, Francisco X Real15, Aldo Scarpa5, Francesco Sclafani7, John A Windsor16, Koji Yamaguchi17, Christopher Wolfgang18, Colin D Johnson19.   

Abstract

BACKGROUND: Pancreatic cancer is one of the most devastating diseases with an extremely high mortality. Medical organizations and scientific societies have published a number of guidelines to address active treatment of pancreatic cancer. The aim of this consensus review was to identify where there is agreement or disagreement among the existing guidelines and to help define the gaps for future studies.
METHODS: A panel of expert pancreatologists gathered at the 46th European Pancreatic Club Meeting combined with the 18th International Association of Pancreatology Meeting and collaborated on critical reviews of eight English language guidelines for the clinical management of pancreatic cancer. Clinical questions (CQs) of interest were proposed by specialists in each of nine areas. The recommendations for the CQs in existing guidelines, as well as the evidence on which these were based, were reviewed and compared. The evidence was graded as sufficient, mediocre or poor/absent.
RESULTS: Only 4 of the 36 CQs, had sufficient evidence for agreement. There was also agreement in five additional CQs despite the lack of sufficient evidence. In 22 CQs, there was disagreement regardless of the presence or absence of evidence. There were five CQs that were not addressed adequately by existing guidelines.
CONCLUSION: The existing guidelines provide both evidence- and consensus-based recommendations. There is also considerable disagreement about the recommendations in part due to the lack of high level evidence. Improving the clinical management of patients with pancreatic cancer, will require continuing efforts to undertake research that will provide sufficient evidence to allow agreement.
Copyright © 2015. Published by Elsevier India Pvt Ltd.

Entities:  

Keywords:  Chemotherapy; Guidelines; Pancreatic cancer; Pathology; Radiation; Surgery

Mesh:

Substances:

Year:  2015        PMID: 26699808     DOI: 10.1016/j.pan.2015.10.013

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  24 in total

1.  Population-based observational study of acute pancreatitis in southern England.

Authors:  Alex Mirnezami; Ben Knight; Brendan Moran; Fergus Noble; Graham Branagan; John Primrose; Katherine Pearson; Malcolm West; Nathan Curtis; Phil Pucher; Ramsey Cuttress; Sian Pugh; Tim Underwood
Journal:  Ann R Coll Surg Engl       Date:  2019-07-30       Impact factor: 1.891

2.  Radiofrequency ablation for locally advanced pancreatic cancer: SMAD4 analysis segregates a responsive subgroup of patients.

Authors:  Salvatore Paiella; Giuseppe Malleo; Ivana Cataldo; Clizia Gasparini; Matteo De Pastena; Giulia De Marchi; Giovanni Marchegiani; Borislav Rusev; Aldo Scarpa; Roberto Girelli; Alessandro Giardino; Isabella Frigerio; Mirko D'Onofrio; Erica Secchettin; Claudio Bassi; Roberto Salvia
Journal:  Langenbecks Arch Surg       Date:  2017-10-05       Impact factor: 3.445

Review 3.  Bridging clinic: The initial medical management of patients with newly diagnosed pancreatic cancer.

Authors:  Loveena Sreedharan; Bhaskar Kumar; Anna Jewell; Paul Banim; Andreas Koulouris; Andrew R Hart
Journal:  Frontline Gastroenterol       Date:  2018-10-09

Review 4.  Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions.

Authors:  Aurélien Lambert; Céline Gavoille; Thierry Conroy
Journal:  Therap Adv Gastroenterol       Date:  2017-06-27       Impact factor: 4.409

Review 5.  [Surgical treatment of pancreatic cancer-What is new?]

Authors:  Thomas Schmidt; Orlin Belyaev; Waldemar Uhl; Christiane J Bruns
Journal:  Chirurg       Date:  2022-03-31       Impact factor: 0.955

6.  Ultrasound-guided Percutaneous Core-needle Biopsy of Focal Pancreatic Lesions - Practical Aspectss.

Authors:  Agnieszka Zofia Rogowska
Journal:  J Ultrason       Date:  2022-04-27

7.  Pancreatic surgery during the COVID-19 pandemic 2020-2021: an observational cohort study from a third level referral center.

Authors:  Carsten Palnæs Hansen; Jan Henrik Storkholm; Martin Hylleholt Sillesen; Paul Suno Krohn; Stefan Kobbelgaard Burgdorf; Jens Georg Hillingsø
Journal:  BMC Surg       Date:  2022-05-21       Impact factor: 2.030

8.  A nomogram of preoperative predictors for occult metastasis in patients with PDAC during laparoscopic exploration.

Authors:  Jiachen Ge; Lei Li; Zhaolai Ma; Bin Jiang; Chunhui Yuan; Hangyan Wang; Ying Peng; Dianrong Xiu
Journal:  Gland Surg       Date:  2021-01

Review 9.  Updated therapeutic outcome for patients with periampullary and pancreatic cancer related to recent translational research.

Authors:  Trond A Buanes
Journal:  World J Gastroenterol       Date:  2016-12-28       Impact factor: 5.742

Review 10.  Comparing the diagnostic accuracy of five common tumour biomarkers and CA19-9 for pancreatic cancer: a protocol for a network meta-analysis of diagnostic test accuracy.

Authors:  Long Ge; Bei Pan; Fujian Song; Jichun Ma; Dena Zeraatkar; Jianguo Zhou; Jinhui Tian
Journal:  BMJ Open       Date:  2017-12-26       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.